We would love to hear your thoughts about our site and services, please take our survey here.
In history telling mode, when Matt Johnson joined Avacta from Abcam he had to relocate a young family and pregnant wife. When asked why his reply was simple....same as Alastair’s, ‘opportunity of a life time’. I asked him at their science conference 2 years ago ish were Affimers living up to his expectations his answer was this is science there are always ups and downs but they were far exceeding his expectations out performing the existing antibodies in numerous cases...and facing some unbelieving questioning from Leon Boris said if anyone was in a position to judge he was. What is possibly even better for the future he likened Affimers to being in a sweet shop and having hundreds of jars (applications) to chose from but needing to be really disciplined to only initially work on a few at a time. As I have to keep telling myself over the last 6 months Patience is all that’s needed. As to valuation depends how long we can defend being taken over or diagnostics being sold separately
Unfortunately I can’t add any tech analysis but maybe I can give some background that can add to the discussion. The original agreement with Mologic circa 2016 broke down because Mologic had no money. It seemed appropriate to ask the question to Avacta last May whether Affimers might be used then or in the future in Mologic’s LFD devices, I got a very short answer...No. By October/ November working relationship had been started with I believe the utmost respect being shown by both sides. Quite a change in 6 months. It might be worth more consideration of their (plural) relationship with LSTM. Apparently Mologic and Dr Emily Adam’s have an extremely strong (‘exceptional’) relationship. With everyone involved just trying to get the best results it’s only logical Affimers and Mologic tests would have been tried out together with different variations. Maybe that’s just stating the obvious but presumably the second stage of combining different Mologic and Avacta targets in one test had a more simple first stage? LSTM I believe is central to FIND Uk. The wording of the new Mologic agreement was always interesting. Mologic’s development of an all in one LFD kit does look next stage. On a slight tangent I noted that Paul Waugh was writing a follow up article on the sovereign tests a week ago, I have no idea why he hasn’t published it yet. Just to throw another one in there, last Autumn Avacta were working on second project with Abingdon equally no idea what it was or whether it’s still going. Labroots upcoming Cytiva conference on LFDs has many reps from Cytiva including Klaus of course plus Avacta & Abingdon. No doubt all will eventually be explained in ‘due course’
I have it on good authority that Paul Waugh is working on follow up article. It will be interesting to see what he’s managed to dig up. If he publishes before the weekend he might save us another very long weekend. Confess I still think the last article wasn’t that far out.
What do you make of this one. New procurement published today end April delivery for Augmented reality hardware and services to enable remote engineering services of the LFT production lines?
Repeat previous question if similar machines could tech transfer from GAD of nailed LFT test package to BBI & Abingdon take days/week or two as I’ve been previously told?
I haven’t posted for a while. As my posting history says I lost a lot of money hear in my early investing days believing Andrew Bell. The board, such as it is, has no regard for shareholders only in maintaining their lifestyles at shareholders expense. Nothing changes over the years wash rinse repeat. Am I a bitter ex shareholder who lost 95% of his investment over 5 years odd? Of course I am !!! However I shouldn’t be as it taught me the hard lesson that it’s management that counts. When I confronted Andrew with his list of story failures his response was it was my fault and shareholders like me as we were tired of losing money and he needed new shareholders who were prepared to give him fresh money......and not keep complaining about losing all their investment. So please buyer beware
Obviously the waiting is getting to me but 7 tests per pack and 1 pack allowed per household per day. So that’s 49 tests per week per household. As apparently there are 27.8 million households if every household orders their full amount per week that’s 1,362,200,000. Say 13 weeks till the end of June that’s 17,708,600,000 free tests.
Benx4
I haven’t a clue either. All I can add is that I know they had a Bruker MS in their lab pre Xmas and were working on the protocols. Once again struggling to repeat lab based ‘gold standard’ tests from smaller, simpler machines and general NHS work practices. My complete guess would be data came back within the timescale but test protocols needed further work and they just don’t have the time/risk/reward factor strong enough when compared to the LFDs. Alastair sort of said that in the interview. Talking of data, have we had validation of the Integumen waste water test? Too distracted with everything else going on.
I probably should have said in his opinion and he was referring to LFDs in general so I think more of a confirmation than a climb down. He also seemed confident in his relationship with his European source of data so hopefully he is as you say seeing data in real time, so confidence in the test is becoming more fact by the minute. As has been stated GAD production is being used for final validation,Unprecedented any further thoughts on why tech transfer to GAD is complete and not BBI? Also know Alastair thinks very highly of Mologic (this time round) and their work goes back to at least November. Omega we know from the misplaced tweet is also part of the picture but why no announcement?
Paul Waugh is well connected and I agree with your comments about his article. I’ve spoken to Alastair very recently (last 10 days) of course he gives nothing away but he does remain very confident. He backed up his belief in the performance of his LFD by saying to his knowledge it was globally one of the best 3 LFDs to date. I would really like to know how large a role LSTM & Emily Adam’s has had. No doubt we will find out in ‘due course’
We’ve been thinking about higher level of cash. It certainly can’t be reduced spending. Why wouldn’t milestones being reached, therefore payments, be hidden? One out the box explanation could be upfront payment from the government for licensing Affimers. It does make sense and just about fits the timetable
Apologies PExpert but haven’t been following posts but if you are referring to our first clinical trial then the PreCISION technology doesn’t contain Affimers so more patience needed. However we do have other dark horses running. Moderna’s star has certainly risen with the success of their tech in producing a successful COVID vaccine not to mention billions of cash flow. They were the first to collaborate with Avacta back in, without checking, 2015. After working with them for 4 years the further licence was signed two years ago. Avacta say they have no vision of what Moderna’s plans are and COVID has put many projects on hold. But there remains the possibility of Moderna being the first to take Affimers into the clinic potentially this year. Apparently Avacta will only be informed if and when a related product goes in to the clinic. South Korea is the other dark horse. We have begun to get known there so whether it’s our partners performing a miracle and getting Affimers into the clinic this year or production of our LFDs or just another collaboration watch this space
SD
Couldn’t agree more. Validation of Affimers on the world stage plus cash flow to progress. I was fortunate enough to attend the Avacta science day a couple of years ago. ‘Matt’ was adamant Affimers outperform antibodies in numerous different diagnostic scenarios. As he said with his Abcam background if anyone should know, he should. ‘Bill’ does give the impression of a mad scientist but his excitement over TMAC was tangible. If I understand him correctly Affimer conjugates with a selection of ‘warheads’ using the PreCISION technology were potentially a cure not just a treatment for many cancers. If their LFDs and for that matter BAMS are indeed world leading the resulting cash flow and global acceptance of the Affimer technology would bring truly mind boggling success. Please note still very big IFFs.